{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T08:00:57Z","timestamp":1740124857080,"version":"3.37.3"},"reference-count":5,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2023,5,4]],"date-time":"2023-05-04T00:00:00Z","timestamp":1683158400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,5,4]],"date-time":"2023-05-04T00:00:00Z","timestamp":1683158400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Impot Res"],"published-print":{"date-parts":[[2024,4]]},"DOI":"10.1038\/s41443-023-00713-5","type":"journal-article","created":{"date-parts":[[2023,5,4]],"date-time":"2023-05-04T12:07:09Z","timestamp":1683202029000},"page":"171-172","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["\u201cCan we try to avoid surgery first?\u201d\u2014Real-world experience with surgery for Peyronie\u2019s disease in the post-intralesional collagenase setting"],"prefix":"10.1038","volume":"36","author":[{"given":"Reza","family":"Kianian","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keith V.","family":"Regets","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7833-7071","authenticated-orcid":false,"given":"Jesse N.","family":"Mills","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1199-0615","authenticated-orcid":false,"given":"Sriram V.","family":"Eleswarapu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,5,4]]},"reference":[{"key":"713_CR1","doi-asserted-by":"publisher","first-page":"973394","DOI":"10.3389\/fphar.2022.973394","volume":"13","author":"F Zhang","year":"2022","unstructured":"Zhang F, Xiong Y, Wang W, Wu C, Qin F, Yuan J. The efficacy and safety of intralesional injection of collagenase Clostridium histolyticum for Peyronie\u2019s disease: a meta-analysis of published prospective studies. Front Pharmacol. 2022;13:973394.","journal-title":"Front Pharmacol"},{"key":"713_CR2","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1093\/jsxmed\/qdac030","volume":"20","author":"MK Li","year":"2023","unstructured":"Li MK, Sigalos JT, Yoffe DA, Modiri N, Hu MY, Gaither TW, et al. Multiple courses of intralesional collagenase injections for Peyronie disease: a retrospective analysis. J Sex Med. 2023;20:200\u20134.","journal-title":"J Sex Med"},{"key":"713_CR3","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1111\/jsm.12721","volume":"12","author":"LA Levine","year":"2015","unstructured":"Levine LA, Larsen SM. Surgical correction of persistent Peyronie\u2019s disease following collagenase Clostridium histolyticum treatment. J Sex Med. 2015;12:259\u201364.","journal-title":"J Sex Med"},{"key":"713_CR4","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-80551-3","volume":"11","author":"A Cocci","year":"2021","unstructured":"Cocci A, Ralph D, Djinovic R, Hatzichristodoulou G, Morelli G, Salonia A, et al. Surgical outcomes after collagenase Clostridium histolyticum failure in patients with Peyronie\u2019s disease in a multicenter clinical study. Sci Rep. 2021;11:166.","journal-title":"Sci Rep"},{"key":"713_CR5","doi-asserted-by":"publisher","first-page":"1421","DOI":"10.1016\/j.jsxm.2019.06.010","volume":"16","author":"K Wymer","year":"2019","unstructured":"Wymer K, Kohler T, Trost L. Comparative cost-effectiveness of surgery, collagenase clostridium histolyticum, and penile traction therapy in men with Peyronie\u2019s disease in an era of effective clinical treatment. J Sex Med. 2019;16:1421\u201332.","journal-title":"J Sex Med"}],"container-title":["International Journal of Impotence Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41443-023-00713-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41443-023-00713-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41443-023-00713-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,18]],"date-time":"2024-03-18T12:06:30Z","timestamp":1710763590000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41443-023-00713-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,4]]},"references-count":5,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,4]]}},"alternative-id":["713"],"URL":"https:\/\/doi.org\/10.1038\/s41443-023-00713-5","relation":{},"ISSN":["0955-9930","1476-5489"],"issn-type":[{"type":"print","value":"0955-9930"},{"type":"electronic","value":"1476-5489"}],"subject":[],"published":{"date-parts":[[2023,5,4]]},"assertion":[{"value":"15 April 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 April 2023","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 April 2023","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 May 2023","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"JNM serves as a consultant to Boston Scientific Corporation, Endo Pharmaceuticals, and Halozyme Therapeutics and receives compensation. KVR serves as a speaker for Boston Scientific Corporation and Halozyme Therapeutics and receives compensation. RK and SVE declare no potential conflicts of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}